MENLO PARK, Calif., Sept. 29, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives today announced Clinical Ophthalmology has published data from a subgroup analysis of the OLYMPIA trial, which showed a single treatment with the TearCare System led to superior symptoms relief across the following primary symptoms endpoints (Ocular Surface Disease Index – OSDI, Symptom Assessment in Dry Eye – SANDE, Eye Dryness – ED) compared to a LipiFlow application in patients with more severe forms of DED due to meibomian gland dysfunction (MGD).1
“Since obstruction of the meibomian glands is the underlying cause of MGD or evaporative dry eye, thorough and comprehensive clearance of the obstruction and the restoration of gland health and meibum production is the preferred treatment. There are different technologies available to address MGD and the unique technological design and procedural differences will naturally impact clinical outcomes and success rates. OLYMPIA demonstrated that the differentiated TearCare technology delivers differentiated clinical outcomes,” said Preeya K. Gupta, M.D., Managing Director of Triangle Eye Consultants, Raleigh, N.C. and first author on the published OLYMPIA study. “We are pleased to see that not only was TearCare able to show a clinically meaningful benefit across all DED patients regardless of severity of disease, but it also demonstrated superior symptoms outcomes among those dry eye patients with advanced disease. The subgroup analysis within OLYMPIA confirms the consistently strong clinical outcomes that many clinicians and I are seeing in our dry eye patients treated with the TearCare System.”
The OLYMPIA study was a multicenter, masked, randomized controlled trial in which 235 participants received either a single TearCare treatment (n = 115) or a single LipiFlow treatment (n = 120) and were followed for one-month post-treatment. Signs and symptoms were assessed across widely accepted endpoints, including the Ocular Surface Disease Index (OSDI), Symptom Assessment in Dry Eye (SANDE), Tear Breakup Time (TBUT) and Eye Dryness (ED) questionnaires at baseline and at one month. At one month, both treatments demonstrated a statistically significant improvement in all primary and secondary endpoints.2
In the subset of more severe patients (MGSS <7) with similar OSDI baseline, those receiving TearCare treatment (n=56) achieved an OSDI score reduction of -31.0 versus -21.4 for those that received LipiFlow treatment (n=65), a statistically significant difference in OSDI symptoms improvements in favor of TearCare. The mean reduction from baseline in SANDE frequency scores also favored a TearCare reduction of 51.9 versus LipiFlow’s 41.5, another statistically significant difference in favor of TearCare. In evaluation of the Eye Dryness Scores within this more severe subgroup, the authors reported the treatment effect of TearCare also trended in favor of TearCare with a mean ED score difference of 8.9 (p=0.071) when compared to LipiFlow.
“As payors evaluate appropriate coverage and reimbursement for select MGD treatments, like TearCare, that are being rigorously clinically evaluated through thoughtfully designed RCTs like OLYMPIA (TearCare/device vs LipiFlow/device) and Sahara (TearCare/device vs Restasis/drug), our patients currently paying out of pocket for heat and expression MGD treatment have high expectations for noticeable improvement,” said Marc Bloomenstein, O.D., Schwartz Laser Center. “The evidence provided in this OLYMPIA subgroup analysis reinforces my confidence in TearCare as my MGD treatment of choice across all patient populations, including the more challenging advanced dry eye patients. Hopefully these study results will encourage my colleagues to establish proficiency in meibomian gland expression following the delivery of therapeutic heat delivery to the eyelids.”
“We are encouraged by the superior clinical findings in this subgroup analysis of advanced dry eye patients from the OLYMPIA trial,” said Paul Badawi, CEO of Sight Sciences. “TearCare’s intuitive design enables clinicians to thoroughly and comprehensively address the root causes of the signs and symptoms of dry eye due to MGD and these data further confirm our confidence in the clinical and economic value that TearCare brings to patients, providers and payors. On the heels of the publication of this superior symptoms data from OLYMPIA, we also announced the completion of patient enrollment in Sahara, our second major RCT where we are comparing TearCare to the standard of care in dry eye, Restasis. We look forward to the readout of TearCare (device) vs Restasis (drug) in the summer of 2023.”
* LipiFlow is a trademark of Johnson & Johnson
1. Holland EJ, Loh J, Bloomenstein M, et al. A comparison of TearCare and LipiFlow systems in reducing dry eye disease symptoms associated with meibomian gland disease. Clin Ophthalmol. 2022; 16:2861-2871. doi:10.2147/OPTH.S368319
2. Gupta PK, Holland EJ, Hovanesian J, et al. TearCare for the treatment of meibomian gland dysfunction in adult patients with dry eye disease: a masked randomized controlled trial. Cornea. 2022;41(4):417-426. doi:10.1097/ICO.0000000000002837
About Sight Sciences
Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world’s most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company’s OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world’s leading cause of irreversible blindness. The Company’s TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by an eye care professional to address the leading cause of dry eye disease. For more information, visit www.sightsciences.com.
About the TearCare® System
The TearCare System is FDA cleared and indicated for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands.
The TearCare System is the only device designed to evacuate obstructed meibomian glands while harnessing a natural blink experience. The system is comprised of single-use, universally fitting SmartLids™ which are placed on the eyelids to deliver “intelligent therapeutic heat” safely and effectively. The portable SmartHub™ communicates directly with the SmartLids to precisely control the amount of phase transition heating and the duration of treatment. After 15 minutes of therapeutic heat, the Clearance Assistant forceps allows the ECP to control expression of the stagnant, obstructed meibum expertly and precisely by targeting individual meibomian glands while obtaining full visual confirmation of the success of this personalized treatment.
This press release, together with other statements and information publicly disseminated by the Company, contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 and includes this statement for purposes of complying with these safe harbor provisions. Any statements made in this press release or during the earnings call that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies. These statements often include words such as “anticipate,” “expect,” “suggests,” “plan,” “believe,” “intend,” “estimates,” “targets,” “projects,” “should,” “could,” “would,” “may,” “will,” “forecast” and other similar expressions. We base these forward-looking statements on our current expectations, plans and assumptions that we have made in light of our experience in the industry, as well as our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances at such time. Although we believe that these forward-looking statements are based on reasonable assumptions at the time they are made, you should be aware that many factors could affect our business, results of operations and financial condition and could cause actual results to differ materially from those expressed in the forward-looking statements. These statements are not guarantees of future performance or results. The forward-looking statements are subject to and involve risks, uncertainties and assumptions, and you should not place undue reliance on these forward-looking statements. These forward-looking statements include, but are not limited to, statements concerning the following: estimates of our total addressable market, future revenue, expenses, capital requirements, and our needs for additional financing; our ability to enter into and compete in new markets; execution of our market strategies; the impact of the COVID-19 pandemic on our business, our customers’ and suppliers’ businesses and the general economy; our ability to compete effectively with existing competitors and new market entrants; our ability to scale our infrastructure; our ability to manage and grow our business by expanding our sales to existing customers or introducing our products to new customers; our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement; potential effects of extensive government regulation; our abilities to obtain and maintain regulatory approvals and clearances for our products that support our revenue projections, business strategies and growth; our ability to successfully execute our clinical trial roadmap; our ability to obtain and maintain sufficient reimbursement for our products; our abilities to protect and scale our intellectual property portfolio; our ability to hire and retain key personnel; our ability to obtain financing in future offerings; the volatility of the trading price of our common stock; our expectation regarding the time during which we will be an emerging growth company under the Jumpstart Our Business Startups Act (the “JOBS Act”); our ability to maintain proper and effective internal controls; and the other important factors discussed under the caption “Risk Factors” in our filings with the U.S. Securities and Exchange Commission, as may be updated from time to time in subsequent filings. These cautionary statements should not be construed by you to be exhaustive and are made only as of the date of this press release. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.